ASK 1 Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
4-Methyl-3-(trifluoromethyl)benzoic acid | 261952-01-6 | sc-262082 sc-262082A | 5 g 25 g | $90.00 $334.00 | ||
Small molecule ASK1 inhibitor with a specific mechanism of action. M2708 inhibits ASK1 activity and the downstream JNK and p38 MAPK pathways. This compound has potential therapeutic applications in inflammatory diseases and cancer. | ||||||
Ulixertinib | 869886-67-9 | sc-507296 | 10 mg | $176.00 | ||
Potent and selective ASK1 inhibitor. Ulixertinib targets ASK1 and inhibits its activity, leading to the suppression of JNK and p38 MAPK signaling pathways. By blocking ASK1, Ulixertinib reduces apoptosis and inflammation. The compound is being studied for its potential therapeutic applications in cancer and inflammatory diseases. | ||||||
GSK461364 | 929095-18-1 | sc-364504 sc-364504A | 10 mg 50 mg | $500.00 $1540.00 | ||
Small molecule inhibitor that specifically targets ASK1. GSK 461364 inhibits ASK1 activity, leading to the suppression of the JNK and p38 MAPK pathways. By blocking ASK1, this compound reduces apoptosis and inflammation. GSK 461364 has potential therapeutic implications in various diseases, particularly in the context of neurodegenerative disorders and inflammatory conditions. | ||||||
D-JNKI-1 | 1445179-97-4 | sc-507347 | 10 mg | $620.00 | ||
Small molecule inhibitor that targets ASK1. JNKi-1 inhibits ASK1 activity, leading to the suppression of the JNK and p38 MAPK pathways. By blocking ASK1, JNKi-1 reduces apoptosis and inflammation. This compound has potential therapeutic implications in cancer and inflammatory diseases. | ||||||
LY2228820 | 862507-23-1 | sc-364525 | 5 mg | $191.00 | 1 | |
Potent and selective ASK1 inhibitor. Ralimetinib targets ASK1 and inhibits its activity, leading to the suppression of JNK and p38 MAPK signaling pathways. By blocking ASK1, Ralimetinib reduces apoptosis and inflammation. The compound is being studied for its potential therapeutic applications in cancer and inflammatory diseases. | ||||||
BMS 582949 | 623152-17-0 | sc-507348 | 5 mg | $510.00 | ||
Small molecule ASK1 inhibitor with a specific mechanism of action. BMS 582949 inhibits ASK1 activity and the downstream JNK and p38 MAPK pathways. This compound has potential therapeutic applications in inflammatory diseases and cancer. | ||||||
MEK 162 | 606143-89-9 | sc-488879 | 10 mg | $306.00 | ||
Potent and selective ASK1 inhibitor. Binimetinib targets ASK1 and inhibits its activity, leading to the suppression of JNK and p38 MAPK signaling pathways. By blocking ASK1, Binimetinib reduces apoptosis and inflammation. The compound is being studied for its potential therapeutic applications in cancer and inflammatory diseases. | ||||||
TAK 715 | 303162-79-0 | sc-362799 sc-362799A | 10 mg 50 mg | $185.00 $781.00 | ||
Inhibits ASK1 through a specific mechanism. TAK-715 targets ASK1 and inhibits its activity, leading to the suppression of JNK and p38 MAPK pathways. By blocking ASK1, TAK-715 reduces apoptosis and inflammation. The compound has potential therapeutic applications in various inflammatory and immune-related disorders. | ||||||